Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

ABL Bio, which is developing new drugs based on a dual antibody ... Lee said, “During a meeting held during the JP Morgan Healthcare Conference (JPM 2025) this month, global big pharmaceutical ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...

Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Morgan Stanley (NYSE:MS) updated its outlook on Kirin Holdings Co Ltd (2503:JP) (OTC: KNBWY), raising the company's price target from ¥2,200 to ¥2,250, while sustaining an Equalweight rating on the ...

Thermo Fisher Scientific should be safe. RFK Jr. may disrupt Big Pharma, but he’s unlikely to cause research to completely ...

JPMorgan Chase & Co. grew its position in shares of Bioceres Crop Solutions Corp. (NASDAQ:BIOX – Free Report) by 49.3% in the ...

This year’s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event.